Managing Director

Head of China Equity Capital Markets and Syndicate

Jefferies

Education

•           Bachelor of Business Administration (Honors) from University of Michigan’s Ross School of Business

Experiences

Alex is a veteran ECM banker for over 20 years, assisting Greater China/Asian issuers across all sectors to raise billions of capital. Based out of HK, he spent his first 5 years at UBS, and another 9 years at J.P. Morgan, where he spearheaded the capital markets effort for corporates especially in the healthcare, FIG, and consumer sectors.

Witnessing the strong market momentum from the first wave of Chapter 18A biotech listings in HK, Alex joined Jefferies as the Head of China ECM and Syndicate in the end of 2018, where he leveraged the Firm’s strength in healthcare globally to build out its China franchise. Since then, he has helped 50+ issuers in North Asia raise c.$25 billion, of which more than half of those were in the healthcare/biotech sector.

At Jefferies, Alex has led numerous landmark healthcare ECM transactions, notably:

•           HutchMed's $618mm HK IPO - the largest tri-listing in HK

•           DualityBio’s $243mm HK IPO - reopened the Chapter 18A market in Apr 2025 after almost 3 years of biotech IPO draught in HK

•           Xtalpi’s $133mm HK IPO, the first Chapter 18C listing in HK

•           Led all China-into-US biotech IPOs since 2020 (Zai Lab, I-Mab, Legend Biotech, Gracell, Adagene, ConnectBio, Lianbio)

Back